Agios Pharmaceuticals Inc (AGIO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David Paul Schenkein
Employees:
482
88 SIDNEY STREET, CAMBRIDGE, MA 02139
617-649-8600

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in applying scientific leadership in the field of cellular metaboli® to transform the lives of patients with cancer and rare genetic disorders of metabolism. Its products include IDH1 AND IDH2, PKR, II D-2 hydroxyglutaric aciduria, AG-221 and AG-120. The comany was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 1.8 Billion Shares Outstanding54.308 Million Avg 30-day Volume 582.596 Thousand
P/E Ratio2.2626 Dividend Yield0.0 EPS-1.56
Price to Revenue0.0 Debt to Equity0.0 EBITDA-320.336 Million
Price to Book Value1.5637 Operating Margin0.0 Enterprise Value1.234 Billion
Current Ratio24.404 EPS Growth4.891 Quick Ratio24.202
1 Yr BETA 0.7137 52-week High/Low 62.16 / 29.21 Profit Margin0.0
Operating Cash Flow Growth17.8582 Altman Z-Score11.9158 Free Cash Flow to Firm -151.489 Million
View SEC Filings from AGIO instead.

View recent insider trading info

Funds Holding AGIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AGIO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

10 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CAR BRUCE CHIEF SCIENTIFIC OFFICER

  • Officer
12,762 2022-01-06 2

BURNS JAMES WILLIAM CHIEF LEGAL OFFICER

  • Officer
8,261 2022-01-01 1

PODDAR RICHA CHIEF COMMERCIAL OFFICER

  • Officer
150 2021-12-06 1

BILLER JONATHAN CHIEF FINANCIAL OFFICER

  • Officer
20,553 2021-12-03 2

GHEUENS SARAH CHIEF MEDICAL OFFICER

  • Officer
4,881 2021-12-02 2

WASHBURN THEODORE JAMES JR. PRINCIPAL ACCOUNTING OFFICER

  • Officer
2,515 2021-08-01 1

ALENSON CARMAN PRINCIPAL ACCOUNTING OFFICER

  • Officer
3,555 2021-06-21 6

BOWDEN CHRISTOPHER CHIEF MEDICAL OFFICER

  • Officer
16,479 2021-06-18 8

MARAGANORE JOHN

  • Director
28,443 2021-05-28 2

FOSTER-CHEEK KAYE I

  • Director
7,164 2021-05-28 2

CLARK IAN T

  • Director
4,964 2021-05-28 2

CLANCY PAUL J

  • Director
4,964 2021-05-28 2

SCHENKEIN DAVID P

  • Director
464,131 2021-05-28 4

HO MAYKIN

  • Director
4,964 2021-05-28 2

SCADDEN DAVID

  • Director
5,535 2021-05-28 2

MILES DARRIN CHIEF COMMERCIAL OFFICER

  • Officer
7,209 2021-05-14 5

FOUSE JACQUALYN A CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
58,363 2021-02-14 2

HIRSCH ANDREW CHIEF FINANCIAL OFFICER

  • Officer
24,272 2020-04-22 0

CELGENE CORP /DE/

CELGENE EUROPEAN INVESTMENT CO LLC

CELGENE SWITZERLAND LLC

CELGENE ALPINE INVESTMENT CO., LLC

  • 10% Owner
7,121,658 2019-11-12 0

BILLER SCOTT CHIEF SCIENTIFIC OFFICER

  • Officer
86,788 2019-06-11 0

HOERTER STEVEN L. CHIEF COMMERCIAL OFFICER

  • Officer
10,941 2019-03-01 0

CANTLEY LEWIS CLAYTON JR.

  • Director
200,596 2017-12-06 0

NELSEN ROBERT

  • Director
109,230 2017-03-03 0

COLE DOUGLAS G.

  • Director
2,778 2016-08-10 0

TESSIER-LAVIGNE MARC

  • Director
0 2016-06-21 0

GODDARD GLENN SENIOR VICE PRESIDENT, FINANCE

  • Officer
0 2016-02-16 0

HIGGONS JOHN DUNCAN CHIEF OPERATING OFFICER

  • Officer
120,834 2016-01-04 0

KARSEN PERRY A

  • Director
0 2015-06-23 0

STARR KEVIN P

  • Director
  • 10% Owner
184,386 2015-02-19 0

ARCH VENTURE FUND VII LP

ARCH VENTURE PARTNERS VII, L.P.

ARCH VENTURE PARTNERS VII, LLC

CRANDELL KEITH

BYBEE CLINTON

  • 10% Owner
No longer subject to file 2015-02-19 0

THIRD ROCK VENTURES LP

THIRD ROCK VENTURES GP, L.P.

TRV GP, LLC

  • 10% Owner
No longer subject to file 2015-02-19 0

CELGENE EUROPEAN INVESTMENT CO LLC

  • 10% Owner
5,242,704 2014-12-16 0

FLAGSHIP VENTURES FUND 2007, L.P.

AFEYAN NOUBAR

KANIA EDWIN M JR

FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

  • 10% Owner
No longer subject to file 2014-06-23 0

CELGENE EUROPEAN INVESTMENT CO LLC

CELGENE CORP /DE/

CELGENE ALPINE INVESTMENT CO., LLC

  • 10% Owner
5,014,059 2014-04-29 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

CAR BRUCE - Officer CHIEF SCIENTIFIC OFFICER

2022-01-10 16:06:35 -0500 2022-01-06 M 3,437 a 10,530 direct -4.6126 0.0 1 -4.6126 2

CAR BRUCE - Officer CHIEF SCIENTIFIC OFFICER

2022-01-10 16:06:35 -0500 2022-01-06 M 3,437 d 3,437 direct

CAR BRUCE - Officer CHIEF SCIENTIFIC OFFICER

2022-01-10 16:06:35 -0500 2022-01-06 F 1,205 $32.58 d 9,325 direct -4.6126 0.0 1 -4.6126 2

BILLER JONATHAN - Officer CHIEF FINANCIAL OFFICER

2021-12-07 16:18:35 -0500 2021-12-03 M 5,753 a 16,623 direct -4.7945 1.9925 1.9925 6 -7.9078 3

BILLER JONATHAN - Officer CHIEF FINANCIAL OFFICER

2021-12-07 16:18:35 -0500 2021-12-03 M 5,753 d 5,753 direct

BILLER JONATHAN - Officer CHIEF FINANCIAL OFFICER

2021-12-07 16:18:35 -0500 2021-12-03 F 1,823 $35.88 d 14,800 direct -4.7945 1.9925 1.9925 6 -7.9078 3

GHEUENS SARAH - Officer CHIEF MEDICAL OFFICER

2021-12-07 16:18:52 -0500 2021-12-02 M 834 a 4,296 direct -4.7945 1.9925 1.9925 6 -7.9078 3

GHEUENS SARAH - Officer CHIEF MEDICAL OFFICER

2021-12-07 16:18:52 -0500 2021-12-02 M 834 d 833 direct

GHEUENS SARAH - Officer CHIEF MEDICAL OFFICER

2021-12-07 16:18:52 -0500 2021-12-02 F 248 $35.00 d 4,048 direct -4.7945 1.9925 1.9925 6 -7.9078 3

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 22:15:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 21:45:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 21:15:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 20:45:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 20:15:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 19:45:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 19:15:04 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 18:45:04 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 18:15:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 17:45:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 17:15:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 16:45:04 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 16:15:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 15:45:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 15:15:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 14:45:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 14:15:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 13:45:02 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 13:15:03 UTC -0.18 0.25 1300000
AGIOS PHARMACEUTICALS INC AGIO 2022-01-14 12:45:03 UTC -0.18 0.25 1300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund AGIO -66.0 shares, $-2310.0 2020-09-30 N-PORT
AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund AGIO -598.0 shares, $-19375.2 2019-09-30 N-PORT
FundVantage Trust- Gotham Master Neutral Fund AGIO -19.0 shares, $-665.0 2020-09-30 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AGIO -8700.0 shares, $-401505.0 2021-09-30 N-PORT
FundVantage Trust- Gotham Hedged Plus Fund AGIO -160.0 shares, $-7384.0 2021-09-30 N-PORT
ETF Series Solutions- The Acquirers Fund AGIO -8125.0 shares, $-381875.0 2021-10-31 N-PORT

Elevate your investments